Injectable buprenorphine during transition out of prison: A pilot partially randomized preference trial protocol.
Justin Berk, Max Cook, Megan Martin...
https://pubmed.ncbi.nlm.nih.gov/40645369/Actively Recruiting
Led by Lifespan · Updated on 2026-05-15
60
Participants Needed
1
Research Sites
21 weeks
Total Duration
This research aims to compare two extended-release buprenorphine medications, Sublocade and Brixadi, for people with opioid use disorder OUD who are leaving prison and reentering the community. The study is a pilot hybrid trial evaluating both how well these treatments work and how feasible and acceptable they are in a correctional setting. It also explores whether allowing participants to choose their medication affects how long they stay in treatment. Participants will receive monthly injections of either Sublocade or Brixadi before and after their release from prison. Some participants will choose which medication they prefer, while others will be randomly assigned to one of the two treatments. The study includes ongoing monthly treatment with flexibility for dosing based on clinical decisions. Participants can switch treatments or stop at any time. During the study, participants will complete surveys and clinical assessments about their treatment experience and satisfaction. Researchers will monitor treatment retention, opioid use through self-report and urine tests, cravings, adverse events, emergency visits, and hospitalizations for six months after release. The study will use these measures to compare the two medications and assess implementation outcomes such as acceptability and feasibility.
CONDITIONS
Injectable Buprenorphine in Prison: A Preference Trial
J
Justin Berk, MD MPH MBA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Lifespan
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Brixadi injection | Sublocade injection | Daily buprenorphine or methadone |
|---|---|---|---|
| What it is | A long‑acting injectable form of buprenorphine given monthly in prison and after release | A monthly pre‑mixed subcutaneous buprenorphine injection administered during incarceration and post‑release | Daily buprenorphine or methadone as typical outpatient MOUD |
| Role in trial | Participants choose or are assigned to receive Brixadi as their preference‑based treatment arm | Participants choose or are assigned to receive Sublocade as their preference‑based treatment arm | Represents usual outpatient MOUD options that would be offered post‑release |
| Primary use | Monthly injectable buprenorphine to support continuity from prison into community | Monthly subcutaneous buprenorphine injection to maintain MOUD during and after incarceration | Daily oral or sublingual MOUD treatment under usual outpatient care |
| How it is given | Monthly injection of Brixadi at preferred injection site such as abdomen, buttocks, or triceps | Monthly subcutaneous injection of Sublocade, dosing determined by provider | Daily dosing of buprenorphine or methadone under routine outpatient protocols |
| Evidence status | Evidence for effectiveness in correctional populations is limited; feasibility data from Rhode Island cohort supports acceptability | Limited evidence in correctional populations; retrospective data show retention and minimal diversion | Daily buprenorphine or methadone demonstrates strong evidence for reducing overdose and improving retention |
| Important risks | Injection site reactions and unknown broader safety profile in incarcerated settings | Some injection site discomfort and potential adverse effects reported | Known opioid agonist safety profile; risks include dependence and withdrawal if stopped abruptly |
| Important limitations | Small sample, partially randomized design, generalizability outside Rhode Island is uncertain | Same limitations apply: pilot design with small N and regional context | Daily MOUD may face adherence, diversion or continuity issues post‑release |
| Patient impact | May support better continuity into community with less frequent dosing and reduced diversion potential | Likely to improve retention post‑release compared to daily dosing by reducing clinic visit burden | Daily MOUD is established to reduce overdose risk and support long‑term recovery |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 months or until study completion
Participants receive monthly injectable buprenorphine (either Sublocade or Brixadi) prior to release from prison and monthly after release. Participants may change treatments or discontinue at any time.
Monthly visits for injections before and after release
Duration - Up to 3 months post-release
Participants are monitored for treatment retention, satisfaction, opioid use, and healthcare utilization during and after the intervention period.
Visits and assessments during and up to 3 months post-treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Justin Berk, Max Cook, Megan Martin...
https://pubmed.ncbi.nlm.nih.gov/40645369/Lifespan
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor